Kaitlyn M. Fishman

Phase I study of the aurora A kinase inhibitor alisertib with induction chemotherapy in patients with acute myeloid leukemia

Traci M. Blonquist, D. Neuberg, T. Graubert, 2016, Haematologica.

Alisertib plus induction chemotherapy in previously untreated patients with high-risk, acute myeloid leukaemia: a single-arm, phase 2 trial.

Traci M. Blonquist, D. Neuberg, T. Graubert, 2019, The Lancet. Haematology.

Cabozantinib is well tolerated in acute myeloid leukemia and effectively inhibits the resistance‐conferring FLT3/tyrosine kinase domain/F691 mutation

Traci M. Blonquist, D. Neuberg, K. Ballen, 2018, Cancer.

Nutrition matters

Emily Kirby, Kaitlyn M. Fishman, R. Hastings, 2000, Nursing management.